07 August 2013 20:41 [Source: ICIS news]
By Joseph Chang
NEW YORK (ICIS)--US renewable chemicals company OPX Biotechnology (OPXBIO) is targeting commercialisation of a bio-based specialty chemical in partnership with Germany-based Evonik within four years, the chief executive of OPXBIO said on Wednesday.
“We have a very specific target chemical we’re working on, but the technology is more broadly applicable,” said Charles Eggert, president and CEO of OPXBIO.
“While it’s a specialty chemical, it doesn’t mean small volume. The goal is to eventually supply high volumes,” he added, while declining to name the chemical.
On 14 May, OPXBIO and Evonik announced an agreement to jointly develop certain bio-based specialty chemicals. The companies did not release details on which chemicals.
“Both Evonik and OPXBIO will have the freedom to use the technology we jointly develop to create additional partnerships or develop technologies of our own,” explained Eggert.
OPXBIO and Evonik research personnel will be working together in each others’ laboratories, said David Hogsett, vice president of R&D and chief technology officer at OPXBIO.
“There will be technology transfer and joint tracking of progress,” he noted.
The target chemical and other specialty chemicals will be produced via fermentation of sugars, said Eggert.
OPXBIO also has a joint development agreement with US-based Dow Chemical focused on bio-based acrylic acid. However, the agreement with Dow is an exclusive one for bio-based acrylic acid.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections